Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945338 | 0.88 | NPC1 (0.56) | NPC1RAB9ACASP3HTTL3MBTL1 | |
| SCHEMBL16609952 | 0.86 | NPC1 (0.53) | NPC1RAB9ACASP3HTTL3MBTL1 | |
| SCHEMBL31455060 | 0.81 | NPC1 (0.55) | NPC1RAB9ACASP3L3MBTL1POLB | |
| SCHEMBL28355514 | 0.79 | MGLL (0.55) | NPC1RAB9ACASP3HTTL3MBTL1 | |
| SCHEMBL3045704 | 0.79 | NPC1 (0.65) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL5716053 | 0.77 | RAB9A (0.63) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL7008912 | 0.77 | NPC1 (0.59) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL16609950 | 0.77 | NPC1 (0.44) | NPC1RAB9ACASP3HTTL3MBTL1 | |
| SCHEMBL3986319 | 0.76 | NPC1 (0.55) | NPC1RAB9ACASP3HTTL3MBTL1 | |
| SCHEMBL5945330 | 0.76 | NPC1 (0.55) | NPC1RAB9ACASP3HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |